6 documents found, page 1 of 1
Disparities in the organisation of national healthcare systems for treatment of...
Michelsen, Brigitte; Østergaard, Mikkel; Nissen, Michael John; Ciurea, Adrian; Möller, Burkhard; Midtbøll Ørnbjerg, Lykke; Horák, PavelBackground: Studies on national policies for biologics are warranted. Objectives: To map and compare national healthcare set-ups for prescription, start, switch, tapering, and discontinuation of biologic/targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in patients with psoriatic arthritis and axial spondyloarthritis across Europe, and assess the healthcare set-ups in relation to countries' soci...
EULAR recommendations for the management of rheumatoid arthritis with synthetic...
Smolen, Josef S.; Landewé, Robert B. M.; Bergstra, Sytske Anne; Kerschbaumer, Andreas; Sepriano, Alexandre; Aletaha, Daniel; Caporali, RobertoObjectives: To provide an update of the EULAR rheumatoid arthritis (RA) management recommendations addressing the most recent developments in the field. Methods: An international task force was formed and solicited three systematic literature research activities on safety and efficacy of disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids (GCs). The new evidence was discussed in light of the last...
Effectiveness and treatment retention of TNF inhibitors when used as monotherap...
Lindström, Ulf; Di Giuseppe, Daniela; Delcoigne, Bénédicte; Glintborg, Bente; Möller, Burkhard; Ciurea, Adrian; Pombo-Suarez, ManuelBackground: Comedication with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) during treatment with tumour necrosis factor inhibitors (TNFi) is extensively used in psoriatic arthritis (PsA), although the additive benefit remains unclear. We aimed to compare treatment outcomes in patients with PsA treated with TNFi and csDMARD comedication versus TNFi monotherapy. Methods: Patients with P...
Impact of discordance between patient’s and evaluator’s global assessment on tr...
Michelsen, Brigitte; Ørnbjerg, Lykke Midtbøll; Kvien, Tore K.; Pavelka, Karel; Nissen, Michael J.; Nordström, Dan; Santos, Maria; Koca, Suleyman SerdarObjectives: To assess the impact of 'patient's minus evaluator's global assessment of disease activity' (ΔPEG) at treatment initiation on retention and remission rates of TNF inhibitors (TNFi) in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) patients across Europe. Methods: Real-life data from PsA and axSpA patients starting their first TNFi from 11 countries in the European Spondyloarthritis Re...
Drug retention, inactive disease and response rates in 1860 patients with axial...
Michelsen, Brigitte; Lindström, Ulf; Codreanu, Catalin; Ciurea, Adrian; Zavada, Jakub; Loft, Anne Gitte; Pombo-Suarez, Manuel; Onen, FatosObjectives: To explore 6-month and 12-month secukinumab effectiveness in patients with axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), (2) time since diagnosis and (3) different European registries. Methods: Real-life data from 13 European registries participating in the European Spondyloarthritis R...
EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis
van Steenbergen, Hanna W.; Aletaha, Daniel; Beaart-van de Voorde, Liesbeth J. J.; Brouwer, Elisabeth; Codreanu, Catalin; Combe, BernardBackground: During the transition to rheumatoid arthritis (RA) many patients pass through a phase characterised by the presence of symptoms without clinically apparent synovitis. These symptoms are not well-characterised. This taskforce aimed to define the clinical characteristics of patients with arthralgia who are considered at risk for RA by experts based on their clinical experience. Methods: The taskforce ...